Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Vincent Hurez

Percutaneous BCG Enhances Innate Effector Antitumor Cytotoxicity During Treatment of Bladder Cancer: A Translational Clinical Trial

OncoImmunology

English

TgMAPK1 Is a Toxoplasma Gondii MAP Kinase That Hijacks Host MKK3 Signals to Regulate Virulence and Interferon-Γ-Mediated Nitric Oxide Production

Experimental Parasitology

English

Related publications

A Possible Mechanism of Intravesical BCG Therapy for Human Bladder Carcinoma: Involvement of Innate Effector Cells for the Inhibition of Tumor Growth

Cancer Immunology, Immunotherapy

English

1,25D3 Enhances Antitumor Activity of Gemcitabine and Cisplatin in Human Bladder Cancer Models

English

Who Should Be Included in a Clinical Trial of Screening for Bladder Cancer?

English

Effect of Anticoagulants and Antiplatelet Agents on the Efficacy of Intravesical BCG Treatment of Bladder Cancer: A Systematic Review

Canadian Urological Association Journal

Urology

2013

English

Granulomatous Prostatitis Diagnosed During Intravesical BCG Treatment

Turk Uroloji Dergisi

Urology

2014

English

Study Protocol of a Phase II Clinical Trial of Oral Metformin for the Intravesical Treatment of Non-Muscle Invasive Bladder Cancer

English

A Phase I Study of an Intravesically Administered Immunotoxin Targeting EpCAM for the Treatment of Nonmuscle-Invasive Bladder Cancer in BCG-refractory and BCG-intolerant Patients

Drug Design, Development and Therapy

Drug Discovery

Pharmacology

Pharmaceutical Science

2010

English

Legal Basic of BCG-Therapy for Bladder Cancer in Municipal Polyclinics

Tuberkulëz i bolezni lëgkikh

English

Mp65-17 Intravesical Thalidomide Boosts Bacillus Calmete-Guérin (Bcg) in Non-Muscle Invasive Bladder Cancer Treatment

Journal of Urology

Urology

2017

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Vincent Hurez

Percutaneous BCG Enhances Innate Effector Antitumor Cytotoxicity During Treatment of Bladder Cancer: A Translational Clinical Trial

TgMAPK1 Is a Toxoplasma Gondii MAP Kinase That Hijacks Host MKK3 Signals to Regulate Virulence and Interferon-Γ-Mediated Nitric Oxide Production

Related publications

A Possible Mechanism of Intravesical BCG Therapy for Human Bladder Carcinoma: Involvement of Innate Effector Cells for the Inhibition of Tumor Growth

1,25D3 Enhances Antitumor Activity of Gemcitabine and Cisplatin in Human Bladder Cancer Models

Who Should Be Included in a Clinical Trial of Screening for Bladder Cancer?

Effect of Anticoagulants and Antiplatelet Agents on the Efficacy of Intravesical BCG Treatment of Bladder Cancer: A Systematic Review

Granulomatous Prostatitis Diagnosed During Intravesical BCG Treatment

Study Protocol of a Phase II Clinical Trial of Oral Metformin for the Intravesical Treatment of Non-Muscle Invasive Bladder Cancer

A Phase I Study of an Intravesically Administered Immunotoxin Targeting EpCAM for the Treatment of Nonmuscle-Invasive Bladder Cancer in BCG-refractory and BCG-intolerant Patients

Legal Basic of BCG-Therapy for Bladder Cancer in Municipal Polyclinics

Mp65-17 Intravesical Thalidomide Boosts Bacillus Calmete-Guérin (Bcg) in Non-Muscle Invasive Bladder Cancer Treatment